PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Ovintiv Inc. (OVV)
40.910.33 (-0.80%)
40.40 - 41.05
29.80 - 47.18
2.12M / 3.66M (Avg.)
18.02 | 2.27
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
20.83%
Some net income increase while VET is negative at -55.20%. John Neff would see a short-term edge over the struggling competitor.
74.82%
D&A growth well above VET's 139.08%. Michael Burry would suspect heavier depreciation burdens that might erode net income unless top-line follows suit.
-265.96%
Both lines show negative yoy. Martin Whitman would see an industry or cyclical factor reducing tax deferrals for both players.
-21.74%
Negative yoy SBC while VET is 27.29%. Joel Greenblatt would see less immediate dilution advantage if talent levels remain strong.
-233.33%
Both reduce yoy usage, with VET at -124.41%. Martin Whitman would find an industry or cyclical factor prompting leaner operational approaches.
-221.70%
AR is negative yoy while VET is 0.00%. Joel Greenblatt would see a short-term cash advantage if revenue remains unaffected vs. competitor's approach.
343.06%
Inventory growth of 343.06% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate build that must match future sales to avoid risk.
101.74%
AP growth of 101.74% while VET is zero at 0.00%. Bruce Berkowitz would see a moderate difference that might matter for short-term liquidity if expansions are large.
-233.33%
Both reduce yoy usage, with VET at -124.41%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
-30.77%
Both negative yoy, with VET at -2.97%. Martin Whitman would suspect an overall environment of intangible cleanup or shifting revaluations for the niche.
9.03%
Some CFO growth while VET is negative at -31.79%. John Neff would note a short-term liquidity lead over the competitor.
-30.31%
Negative yoy CapEx while VET is 22.78%. Joel Greenblatt would see a near-term FCF boost unless competitor invests for long-term advantage.
98.14%
Acquisition spending well above VET's 100.00%. Michael Burry would suspect heavier integration risk or short-term free cash flow drain vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-82.58%
Both yoy lines negative, with VET at -850.18%. Martin Whitman suspects a cyclical or strategic rationale for cutting extra invests in the niche.
71.61%
We have mild expansions while VET is negative at -3.65%. John Neff sees competitor possibly divesting or pausing expansions more aggressively.
-200.00%
We cut debt repayment yoy while VET is 13.12%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
No Data
No Data available this quarter, please select a different quarter.
49.44%
Similar buyback growth to VET's 52.11%. Walter Schloss sees parallel capital return priorities or a stable free cash flow for both.